🚨 Trade Update: GE — First Price Target Hit
We recommended GE Aerospace (NYSE: GE) on June 8, 2026, at a buy level of $330.80, with price targets of $355.00 (PT1) and $370.00 (PT2) and a stop-loss at $318.00 on a closing basis.
PT1 has been achieved — the stock closed at $355.12, comfortably above our $355.00 target, after hitting an intraday high of $361.28 — delivering a gain of approximately 7% from the entry level in just over two weeks. PT2 at $370.00 remains in play.
How to manage the position from here: Traders with a conservative risk appetite may consider booking partial profits at current levels. Those looking to ride the remaining momentum can continue holding with a trailing stop at $330.80 (our entry level), making the trade effectively risk-free while leaving room for the move toward PT2.
Bottom line: PT1 hit in just over two weeks — book partial gains or raise your stop to breakeven and aim for PT2 at $370.00.
🚨 Trade Update: CVS — Both Price Targets Hit ✅
We recommended CVS Health Corporation (NYSE: CVS) on April 30, 2026, with a buy level of $84.50 and price targets of $93.00 (PT1) and $99.00 (PT2), with a stop-loss at $79.90 on a closing basis.
Both targets have been achieved — the stock is currently trading around $101.30, comfortably above PT2, after hitting an intraday high of $103.12 — delivering gains of approximately 10% and 17% from the entry level in under two months.
How to manage the position from here: Traders with a conservative risk appetite may consider booking profits at current levels. Those looking to ride the remaining momentum can continue holding with a trailing stop at $99.00 (our PT2), locking in a minimum ~17% gain while leaving room for further upside.
Bottom line: Both targets hit in under two months — book profits or trail your stop to $99.00 and let the rest run.
📋 Trade Update: NVDA — Stopped Out at $211.00
We recommended NVIDIA (NASDAQ: NVDA) on June 2, 2026, at a buy level of $230.00, with price targets of $265.00 (PT1) and $290.00 (PT2) and a stop-loss at $211.00 on a closing basis.
The stock triggered our entry but was unable to sustain momentum above the breakout level. Price reversed and closed below $211.00, triggering our stop-loss for a loss of approximately $19.00 per share (~8%). The stock is currently trading around $208.65.
The bull flag breakout that formed the basis of this trade did not hold, and the broader selling pressure overwhelmed the pattern. With the technical structure now broken, this trade is closed.
Why the stop matters: This setup was structured with a 1:2 to 1:3 risk-reward ratio. Even with this loss, the math behind the system works — controlled losses on the downside, with outsized gains when setups follow through. Discipline on stop-losses is what keeps the edge intact over a full portfolio of trades.
Bottom line: Stop-loss triggered at $211.00 — trade closed with a ~8% loss. On to the next one.
AbbVie Inc. (NYSE: ABBV) just broke out of a multi-month downtrend channel on a powerful ~6.5% single-session surge and looks headed even higher.
As we’ll get to just ahead, the combination of a transformative $10.9 billion Apogee Therapeutics acquisition deepening AbbVie’s immunology and respiratory moat, a clean Q1 2026 earnings beat with raised full-year guidance underscoring the post-Humira growth engine, and a fresh technical breakout makes ABBV one of the more interesting setups on the board. Here’s what’s going on…
The Themes Behind the Move
AbbVie is a global biopharmaceutical company that researches, develops, manufactures, and commercializes therapies across immunology, oncology, neuroscience, aesthetics, and eye care — including blockbusters like Skyrizi and Rinvoq for inflammatory and autoimmune diseases, Botox across both cosmetic and therapeutic indications, and a deep oncology portfolio anchored by Venclexta, Imbruvica, Elahere, and Epkinly.
In plain English, when a hospital network needs to treat moderate-to-severe psoriasis, ulcerative colitis, or rheumatoid arthritis, when an oncologist needs a targeted therapy for blood cancer, or when a neurologist needs a frontline option for chronic migraine or Parkinson’s-related motor fluctuations — AbbVie is one of the very few companies in the world whose portfolio touches all of those needs. Its business hinges on the pace of Skyrizi/Rinvoq adoption, label expansions across new indications, and a steady cadence of M&A and internal pipeline readouts that keep filling the post-Humira growth runway.
ABBV’s latest move reflects a powerful confluence of developments — strategic, commercial, and operational — that have come together in rapid succession to fundamentally reshape the company’s near-term growth trajectory.
| Theme / Catalyst | What Happened | Why Traders Care |
|---|---|---|
| $10.9 billion Apogee Therapeutics acquisition | AbbVie announced a definitive agreement to acquire Apogee Therapeutics for $135.11 per share in cash — roughly a 49% premium to the prior close and one of the largest pharma deals in recent years. The crown jewel is zumilokibart (APG777), a half-life-extended IL-13 monoclonal antibody with strong Phase 2 atopic dermatitis data and promising asthma readouts. Both boards have unanimously approved; deal expected to close in Q3 2026. | This is AbbVie aggressively protecting its immunology dominance post-Humira. Zumilokibart’s every-3-to-6-month dosing profile is a major competitive differentiator versus Sanofi/Regeneron’s Dupixent (an every-two-week injection that generated nearly $18 billion last year). The stock surged ~6.5% on the announcement — the kind of move that reframes the long-term bullish narrative through the 2030s. |
| Q1 2026 earnings beat + raised full-year guidance | AbbVie reported Q1 net revenues of $15.0 billion (+12.4% reported, beating expectations) and adjusted diluted EPS of $2.65 (+7.7% YoY, also a beat). Skyrizi revenues hit $4.48 billion (+29.2% operational) and Rinvoq $2.12 billion (+20.2% operational), more than offsetting Humira’s ~40% decline. Management raised full-year 2026 adjusted EPS guidance to $14.08–$14.28. | This officially confirms AbbVie has bridged the dreaded “Humira patent cliff” — the post-cliff growth engine is real, accelerating, and operating ahead of management’s own internal plan. When a mega-cap pharma raises guidance into a transition year, that’s the kind of execution that supports a sustained re-rating. |
| Sector tailwinds | AbbVie sits squarely at the intersection of three major healthcare megatrends: precision medicine, advanced targeted oncology, and aging-population chronic disease management. The broader pharma M&A cycle is accelerating, with strong underlying demand for targeted immunology and biologics therapies across psoriasis, IBD, atopic dermatitis, and asthma — and AbbVie is also pushing into the ultra-lucrative obesity market via ABBV-295, a long-acting amylin analog with monthly-dosing potential. | As global demographics skew older, baseline demand for AbbVie’s core franchises — immunology, neuroscience, and oncology — is structurally insulated from traditional recessions. And an early-stage obesity asset with monthly dosing could be a massive differentiator versus Eli Lilly and Novo Nordisk’s weekly regimens. |
| Strengthened fundamentals + attractive dividend | FY26 guidance now sits at ~$67.3 billion in revenue and $14.08–$14.28 in adjusted EPS, with Skyrizi and Rinvoq combined growing well above 20% YoY. The balance sheet supports a recently announced $1.78 billion U.S. manufacturing expansion — a $1.4 billion North Carolina campus plus a $380 million North Chicago expansion. Investors also get a quarterly dividend of $1.73 (yield ~3%), with the ex-dividend date on July 15, 2026. | A rare GARP (growth-at-a-reasonable-price) profile — mid-double-digit earnings growth plus a ~3% yield. Companies don’t deploy nearly $2 billion in physical infrastructure unless they’re confident in sustained volume growth across immunology, neuroscience, and obesity for the next decade. |
| Analyst coverage | Among the 25 analysts covering ABBV, the average 12-month price target sits at $253.43, with a high of $298.00 and a low of $214.00. The average target implies roughly 10% upside from current levels around $230 — and the high end of the range implies nearly 30% additional upside. | A wide breadth of Wall Street coverage already lined up to the upside — and the high-end target of $298 suggests there’s still meaningful room for the consensus to drift higher as Skyrizi/Rinvoq beats roll in and the Apogee deal closes. |
| Market conviction signal | ABBV surged ~6.5% in a single session on the Apogee announcement, breaking decisively out of a multi-month downtrend channel on clear volume expansion. The move came as one of the largest pharma deals in recent years was being absorbed by the market — and was accompanied by a sharp rally in Apogee shares as well. | When a roughly $400 billion mega-cap pharma jumps ~6.5% in a single session on M&A and clears a multi-month trendline on volume, that’s the kind of institutional repositioning that typically marks the start of a sustained re-rating — not a one-day pop. |
| Upcoming triggers | Traders are watching Q2 2026 earnings on July 30 (before market open), the Apogee deal close in Q3 2026, the August 14 quarterly dividend payment of $1.73, an expected late-2026 FDA decision on SKYRIZI subcutaneous induction for Crohn’s disease, an upcoming regulatory submission for etentamig in oncology, and additional Phase 3 readouts for Rinvoq across HS, SLE, alopecia areata, and vitiligo. | A staggered set of high-conviction catalysts — earnings, M&A close, a dividend payment, and multiple regulatory readouts — each capable of independently moving the stock through the back half of 2026. |
If needed, swipe or scroll sideways to view the full table.
Put it all together, and ABBV is looking less like a slow-growth pharma laggard chained to a fading Humira franchise and more like a structurally diversified biopharma compounder with accelerating immunology growth, a transformative new pipeline asset, and a defensive dividend underwriting the next leg higher.
The story is getting stronger by the week, but the chart is what could determine whether this move has more room to run in the near term. Here are the bullish technical signals traders should be watching now.
Bullish Technical Signals
#1 Downtrend Channel — Breakout in Progress: On the daily chart, ABBV has spent the past several months carving out a descending channel (purple). After rallying off the lower rail from the May low near $195, price is now pressing into — and lifting off — the upper rail on a wide-range candle with a clear volume expansion. That break attempt lines up almost exactly with the $233.60 trigger, giving you confluence between the channel’s upper boundary and the entry level. A channel break backed by rising volume is what signals the corrective phase is ending: it shifts the burden of proof from sellers to buyers and opens room back toward the prior swing highs.
ABBV – Daily Chart
#2 Price Above MAs: ABBV is trading above both the 50-day SMA ($212.12) and the 200-day SMA ($220.66), placing it back in bullish territory on the daily timeframe. Reclaiming this overhead supply reflects a market that has absorbed selling and is coiling for a directional move, and both averages now sit just beneath price as a layered support zone for buyers to lean on if it pulls back.
#3 Bullish Aroon: The Aroon indicator is pinned to a fully bullish configuration: Aroon Up reads 100 while Aroon Down has collapsed to ~7. In plain terms, the stock is printing fresh highs essentially every session within the lookback window, while new lows have gone stale. That’s about as one-sided as participation gets — buyers fully engaged, sellers absent — and it cleanly corroborates the channel breakout and the TRIX upturn flagged below.
#4 Bullish TRIX: TRIX is a triple-smoothed momentum oscillator built to strip out short-term noise and isolate the underlying trend. It has reclaimed the zero line and is now pushing higher. Holding above zero after a move up from below confirms that momentum — once the day-to-day volatility is filtered away — has flipped decisively positive, lending weight to the breakout rather than fading it.
#5 Bull Flag Breakout: Zooming out to the weekly chart, ABBV shows a flagpole-and-flag structure: a sharp multi-quarter advance through 2024–25, followed by an orderly, downward-sloping consolidation within a narrow parallel channel (pink). Price is now breaking the upper boundary of that channel on a strong weekly candle. Flags are continuation patterns by design — the consolidation digests the prior leg, shakes out weak hands, and resets momentum before the next push. With the stock trading well above both the 50-week SMA ($217.91) and the 200-week SMA ($179.16) — the latter sitting far below price — the longer-term uptrend remains firmly intact.
ABBV – Weekly Chart
#6 Weekly Stochastic Crossover (Momentum Confirmation): On the weekly, %K (94.44) has crossed above %D (83.51), with momentum decisively favoring buyers. Both lines are in overbought territory (>80), so treat this as confirmation of trend strength rather than a fresh oversold entry signal. On a weekly timeframe, sustained readings up here are characteristic of strong trends, not impending reversals — the crossover reinforces that the larger move still has the wind at its back.
#7 Bullish MACD: On the weekly, the MACD line has crossed above its signal line, with the histogram flipping from negative to positive near the zero line. A zero-line-area crossover coming out of a basing phase is an early momentum tell: short-term momentum is now outpacing the longer-term average, pointing the path of least resistance higher.
Risks to Consider
Even strong setups can fail, especially in a large-cap pharma name like AbbVie. A few things could knock the stock off course:
- A breakdown back below the channel breakout level on heavy volume, which would invalidate the bullish trigger
- Negative company-specific news or broader market weakness — any meaningful rotation out of healthcare or risk-off in the broader market would weigh on large-cap pharma names
- Integration and execution risk on the $10.9 billion Apogee acquisition — large biotech deals can introduce dilution, near-term cost pressure, or delays before the assets start contributing meaningfully (management noted the deal is accretive to adjusted EPS only starting in 2032)
- Competition in immunology — other IL-13/TSLP assets, JAK inhibitors, and oral biologics from peers like Eli Lilly could chip away at AbbVie’s market share, particularly in atopic dermatitis
- Manufacturing setbacks — the FDA recently issued a Complete Response Letter (CRL) for trenibotulinumtoxinE (a cosmetic/therapeutic neurotoxin) due to facility issues; while solvable, additional manufacturing-driven delays remain a sector risk
- Drug pricing and policy pressure — large pharma names remain a frequent political target, and any meaningful shift in U.S. drug pricing rules could compress margins on key franchises
- Pipeline and regulatory disappointments — late-stage Rinvoq or Skyrizi readouts that miss expectations, or delays in the obesity (ABBV-295) and oncology (etentamig) programs, could pressure the multiple
- Valuation premium — ABBV is not cheap relative to some pharma peers; any execution miss or sentiment shift could trigger a quick re-rating lower despite the visible growth
The Bottom Line
ABBV is breaking out of a multi-month downtrend channel on the daily chart while simultaneously breaking the upper boundary of a multi-quarter bull flag on the weekly — a dual-timeframe technical setup that historically signals the start of a sustained move higher.
The fundamental story underneath the chart is just as strong: a transformative $10.9 billion Apogee Therapeutics acquisition deepening AbbVie’s immunology and respiratory moat, a Q1 2026 earnings beat with raised full-year guidance confirming the post-Humira growth engine is real, and a ~3% dividend yield backed by Skyrizi and Rinvoq combined growth above 20% YoY.
Combine that with multiple catalysts staggered through the back half of 2026 — Q2 earnings on July 30, the Apogee deal close in Q3, the August dividend payment, and multiple late-2026 regulatory readouts across Crohn’s, oncology, and immunology — and ABBV looks like one of the more compelling risk-reward setups on the board right now.
If this is a trade you want to get in on, here’s how we’d play it. Below you’ll find our exact entry level, both price targets that imply 11%–18% potential upside, and the stop-loss we’re using to manage the downside.
Recommended Trade Setup
| Item | Detail |
|---|---|
| Buy Level | Above approximately $233.60 |
| Price Target 1 | $260.00 — Potential upside: 11% |
| Price Target 2 | $275.00 — Potential upside: 18% |
| Timeframe | Next 3–6 months |
| Stop-Loss | $220.00 on a closing basis |
| Trade Invalidation | Void if price hits stop-loss before entry triggers |
If needed, swipe or scroll sideways to view the full table.
For a risk of approximately $13.60 per share, the target rewards are about $26.40 and $41.40 per share. That makes this roughly a 1:2 and 1:3 risk-reward trade. In other words, the setup offers nearly 2x to 3x more potential upside than downside.
Note on Trade Invalidation: This recommendation stays active only while the underlying technical structure holds. If ABBV closes at or below the $220.00 stop before the $233.60 entry triggers, the trade is automatically invalidated — the support framework underpinning the thesis would have broken down, and re-entry should be considered only on a fresh setup with its own risk parameters.
Happy Trading!
Tara and Greg
🥈 Almost Made the Cut
Two stocks that advanced to the final round and remain on our watchlist:
Super Micro Computer Inc. (NASDAQ: SMCI) — Strong AI infrastructure demand, accelerating Blackwell deployments, and its newly unveiled NVIDIA Vera Rubin platform position SMCI to benefit from the next wave of hyperscale AI data center spending.
REGENXBIO Inc. (NASDAQ: RGNX) — Multiple near-term regulatory and clinical catalysts, including FDA alignment for RGX-121 and positive Phase 3 gene therapy data, create a compelling biotech setup with significant re-rating potential over the coming months.
